Disc Medicine (NASDAQ:IRON) Upgraded at Wall Street Zen

Disc Medicine (NASDAQ:IRON) was upgraded by stock analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report released on Saturday.

Other research analysts have also recently issued research reports about the stock. Wedbush lowered their price target on shares of Disc Medicine from $110.00 to $88.00 and set an “outperform” rating for the company in a report on Tuesday, February 17th. BMO Capital Markets lowered their price target on shares of Disc Medicine from $120.00 to $100.00 and set an “outperform” rating for the company in a report on Tuesday, February 17th. Raymond James Financial reiterated a “market perform” rating on shares of Disc Medicine in a report on Thursday, January 15th. Stifel Nicolaus lowered their price target on shares of Disc Medicine from $125.00 to $110.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Finally, UBS Group reiterated an “overweight” rating on shares of Disc Medicine in a report on Thursday, January 15th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Disc Medicine presently has an average rating of “Moderate Buy” and a consensus target price of $104.80.

Disc Medicine Trading Up 0.8%

NASDAQ IRON opened at $68.85 on Friday. The company has a quick ratio of 21.94, a current ratio of 21.94 and a debt-to-equity ratio of 0.04. Disc Medicine has a 52 week low of $40.00 and a 52 week high of $99.50. The stock has a market capitalization of $2.63 billion, a PE ratio of -11.49 and a beta of 0.91. The firm has a 50 day moving average of $64.41 and a two-hundred day moving average of $76.22.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($1.62) EPS for the quarter, topping the consensus estimate of ($1.69) by $0.07. The firm had revenue of ($19.88) million for the quarter, compared to analyst estimates of $0.15 million. As a group, research analysts expect that Disc Medicine will post -6.68 EPS for the current fiscal year.

Insider Activity at Disc Medicine

In other Disc Medicine news, CFO Jean M. Franchi sold 6,257 shares of the firm’s stock in a transaction that occurred on Tuesday, April 14th. The shares were sold at an average price of $69.24, for a total transaction of $433,234.68. Following the sale, the chief financial officer owned 64,333 shares of the company’s stock, valued at approximately $4,454,416.92. This trade represents a 8.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider William Jacob Savage sold 5,731 shares of the firm’s stock in a transaction that occurred on Monday, April 13th. The stock was sold at an average price of $66.38, for a total transaction of $380,423.78. Following the sale, the insider directly owned 79,480 shares in the company, valued at approximately $5,275,882.40. The trade was a 6.73% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 59,410 shares of company stock valued at $3,840,013 in the last quarter. Company insiders own 3.64% of the company’s stock.

Institutional Trading of Disc Medicine

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IRON. ANTIPODES PARTNERS Ltd acquired a new stake in Disc Medicine during the fourth quarter worth approximately $33,000. Aster Capital Management DIFC Ltd acquired a new position in shares of Disc Medicine in the 3rd quarter valued at $38,000. KBC Group NV acquired a new position in shares of Disc Medicine in the 4th quarter valued at $80,000. Avanza Fonder AB increased its holdings in shares of Disc Medicine by 54.0% in the 3rd quarter. Avanza Fonder AB now owns 1,668 shares of the company’s stock valued at $110,000 after acquiring an additional 585 shares during the period. Finally, Persistent Asset Partners Ltd acquired a new position in shares of Disc Medicine in the 4th quarter valued at $141,000. Institutional investors and hedge funds own 83.70% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.